A Pilot Randomized Placebo-Controlled Study of Pirlindole in the Treatment of Primary Fibromyalgia

REFERENCES

• Bennett R M. Fibromyalgia and the facts. Sense or nonsense. Rheum Dis Clin N Am 1993; 19: 45–59
   PubMed Web of Science ®Google Scholar
• Boissevain M D, McGain G A. Toward an integrated understanding of fibromyalgia syndromes. I. Medical and pathophysiological aspects. Pain 1991; 45: 227–238
   PubMed Web of Science ®Google Scholar
• Bradley L A, Alarcón G S. Arthritis and allied conditions. A textbook of rheumatology. Fibromyalgia., 13th edit., W J Koopman. Williams & Wilkins, Baltimore 1997; 1619–1640
   Google Scholar
• Veale D, Kavanagh G, Fielding J F, Fitzgerald O. Primary fibromyalgia and the irritable bowel syndrome: different expressions of a common pathogenetic process. Br Med J 1991; 30: 220–222
   Google Scholar
• Hench P K. Nonarticular rheumatism. Twenty-second rheumatism review: review of the American and English literature for the years 1973 and 1974. Arthritis Rheum 1976; 19(Suppl)1081–1089
   Google Scholar
• Powers R. Fibromyalgia: an age-old malady begging for respect. J General Intern Med 1993; 8: 93–105
   PubMedGoogle Scholar
• Wolfe F, Smythe H A, Yunus M B, Bennett R M, Bombardier C, Goldenberg D L, Tugwell P, Campbell S M, Abeles M, Clark P, Fam A G, Farber S J, Fiechtner J J, Franklin C M, Gatter R A, Hamaty D, Lessard J, Lichtbroun A S, Masi A T, McCain G A, Reynolds W J, Romano T J, Russell I J, Sheon P P. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 1990; 33: 160–172
   PubMed Web of Science ®Google Scholar
• Wolfe F, Ross K, Anderson J, Russell I J, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19–28
   PubMed Web of Science ®Google Scholar
• Yunus M B, Dailey J W, Aldag J C, Masi A T, Jobe P C. Plasma tryptophan and other amino-acids in primary fibromyalgia: a controlled study. J Rheumatol 1992; 19: 90–94
   PubMed Web of Science ®Google Scholar
• Russell I J, Orr M D, Littman B, Vipraio G A, Alboukrek D, Michalek J E, Lopez Y, MacKillip F. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgial syndrome. Arthritis Rheum 1994; 37: 1593–1601
   PubMed Web of Science ®Google Scholar
• Crofford L J, Pillemer S R, Kalogeras K T, Cash M J, Michelson D, Kling M A, Sternberg E M, Gold P W, Chrousos G P, Wilder R L. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994; 37: 1583–1592
   PubMed Web of Science ®Google Scholar
• Lund N, Bengtsson A, Thorborg P. Muscle tissue oxygen pressure in primary fibromyalgia. Scand J Rheumatol 1986; 15: 165–173
   PubMed Web of Science ®Google Scholar
• Bengtsson A, Henriksson K G. The muscle in fibromyalgia. A review of Swedish studies. J Rheumatol 1989; 19: 144–149
   Google Scholar
• Bengtsson A, Henriksson K G, Larsson J. Reduced high-energy phosphate levels in the painful muscles of patients with primary fibromyalgia. Arthritis Rheum 1986; 29: 817–821
   PubMed Web of Science ®Google Scholar
• White K P, Harth M. An analytical review of 24 controlled clinical trials for fibromyalgia syndrome (FMS). Pain 1996; 64: 211–219
   PubMed Web of Science ®Google Scholar
• Ginsberg F, Mancaux A, Joos E, Vanhove P, Famaey J P. A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia. J Musculoske Pain 1996; 4(3)37–47
   Google Scholar
• Carette S, Bell M J, Reynolds W J, Haraoui B, McCain G A, Bykerk V P, Edworthy S M, Baron M, Koehler B E, Fam A G, Bellamy N, Guimont C. Comparison of amitriptyline, cyclobenzaprine and placebo in the treatment of fibromyalgia: a randomized double-blind clinical trial. Arthritis Rheum 1994; 37: 32–40
   PubMed Web of Science ®Google Scholar
• Wysenbeek A J, Mor F, Lurie Y, Weinberger A. Imipramine for the treatment of fibrositis: a therapeutic trial. Ann Rheum Dis 1985; 44: 752–753
   PubMed Web of Science ®Google Scholar
• Caruso I, Sarzi Puttini P C, Boccassini L, Santandrea S, Locati M, Volpato R, Montrone F, Benvenuti C, Beretta A. Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1987; 15: 154–159
   PubMed Web of Science ®Google Scholar
• Wolfe F, Cathay M A, Hawley D J. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994; 23: 255–259
   PubMed Web of Science ®Google Scholar
• Nørregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995; 61: 445–449
   PubMed Web of Science ®Google Scholar
• Tyber M A. Lithium carbonate augmentation therapy in fibromyalgia. Can Med Assoc J 1990; 143: 902–904
   PubMed Web of Science ®Google Scholar
• Drewes A M, Andreasen A, Jennum P, Nielson K D. Zopiclone in the treatment of sleep abnormalities in fibromyalgia. Scand J Rheumatol 1991; 20: 288–293
   PubMed Web of Science ®Google Scholar
• Jacobsen S, Danneskiold-Samsoe B, Bach Andersen R. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol 1991; 20: 294–302
   PubMed Web of Science ®Google Scholar
• Russell I J, Fletcher E M, Michalek J E, McBroom P C, Hester G G. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam: a double-blind placebo controlled study. Arthritis Rheum 1991; 34: 552–560
   PubMed Web of Science ®Google Scholar
• Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996; 39: 1852–1859
   PubMed Web of Science ®Google Scholar
• Russell I J, Michalek J E, Vipraio G A, Fletcher E M, Javors M A, Bowden C A. Platelet 3H-imipramine uptake receptor density and serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992; 19: 104–109, 1992
   PubMed Web of Science ®Google Scholar
• Russell I J, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992; 35: 550–556
   PubMed Web of Science ®Google Scholar
• Bruhwyler J, Liégeois J F, Géczy J. Pirlindole, a selective reversible inhibitor of monoamine oxidase A. A review of its preclinical properties. Pharmacol Res, (in press)
   Google Scholar
• Bruhwyler J, Monseu M J, Vandekerckhove K, Géczy J. Pirlindole a reversible and selective monoamine oxidase A inhibitor: A retrospective evaluation of its clinical antidepressant profile. Eur J Clin Res, (in press)
   Google Scholar
• Hewett J E, Buckelew S P, Johnson J C, Shaw S E, Huyser B, Fu Y Z. Selection of measures suitable for evaluating change in fibromyalgia clinical trials. J Rheumatol 1995; 22: 2307–2312
   PubMed Web of Science ®Google Scholar
• Goldenberg D L. Treatment of fibromyalgia syndrome. Rheum Dis Clin N Amer 1989; 15: 61–71
   PubMedGoogle Scholar
• Buckelew S P. Fibromyalgia: A rehabilitation approach. Am J Phys Med Rehabil 1989; 68: 37–42
   PubMedGoogle Scholar
• De Wilde J E, Geerts S, Van Dorpe J, Bruhwyler J, Géczy J. A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression. Acta Psych Scand 1996; 94: 404–410
   PubMedGoogle Scholar
• Tanghe A, Geerts S, Van Dorpe J, Brichard B, Bruhwyler J, Géczy J. Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression. Acta Psych Scand, (in press)
   Google Scholar
• De Wilde J, Mertens C, Van Dorpe J, Bruhwyler J, Géczy J. Double-blind randomized controlled pilot study of the efficacy and tolerability of pirlindole, a reversible inhibitor of monoamine oxidase A, and mianserin, in the treatment of depression. Hum Psychopharmac 1997; 12: 41–46
   Google Scholar